# **Complete Summary**

#### **GUIDELINE TITLE**

Position statement on routine laboratory testing before endoscopic procedures.

## **BIBLIOGRAPHIC SOURCE(S)**

ASGE Standards of Practice Committee, Levy MJ, Anderson MA, Baron TH, Banerjee S, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Jagannath S, Lichtenstein D, Shen B, Fanelli RD, Stewart L, Khan K. Position statement on routine laboratory testing before endoscopic procedures. Gastrointest Endosc 2008 Nov;68(5):827-32. [61 references] PubMed

#### **GUIDELINE STATUS**

This is the current release of the guideline.

# **COMPLETE SUMMARY CONTENT**

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis RECOMMENDATIONS EVIDENCE SUPPORTING THE RECOMMENDATIONS BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS **CONTRAINDICATIONS** QUALIFYING STATEMENTS IMPLEMENTATION OF THE GUIDELINE INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT **CATEGORIES** IDENTIFYING INFORMATION AND AVAILABILITY **DISCLAIMER** 

#### SCOPE

#### **DISEASE/CONDITION(S)**

Diseases or conditions requiring gastrointestinal endoscopy

# **GUIDELINE CATEGORY**

Diagnosis Evaluation Management Risk Assessment Screening

#### **CLINICAL SPECIALTY**

Gastroenterology Surgery

#### **INTENDED USERS**

**Physicians** 

## **GUIDELINE OBJECTIVE(S)**

To provide guidance regarding routine laboratory testing before endoscopic procedures

#### **TARGET POPULATION**

Patients undergoing gastrointestinal endoscopy

#### INTERVENTIONS AND PRACTICES CONSIDERED

# Routine Pre-Endoscopy Laboratory Testing\*

- 1. Coagulation studies:
  - Prothrombin time (PT)
  - INR (international normalized ratio)
  - Partial thromboplastin time (PTT)
  - Platelet time
  - Bleeding time
- 2. Chest x-ray
- 3. Electrocardiogram (ECG)
- 4. Blood cross-matching
- 5. Hemoglobin/hematocrit
- 6. Urinalysis
- 7. Pregnancy testing
- 8. Serum chemistry testing

#### **MAJOR OUTCOMES CONSIDERED**

- Incidence of abnormal laboratory test results
- Correlation of abnormal laboratory test results to procedural outcome

#### **METHODOLOGY**

#### METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

<sup>\*</sup>Note: No evidence supports routine preprocedure testing; therefore, none of these tests is recommended routinely (see "Major Recommendations" section for procedures to perform on a selective basis).

#### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

MEDLINE and PubMed databases were used to search publications related to endoscopy by using the key words "endoscopy" and "laboratory" with each of the following: "preanesthesia," "preoperative," "routine," "screening," and "testing." The search was supplemented by accessing the "related articles" feature of PubMed with articles identified on MEDLINE and PubMed as the references. Pertinent studies published in English were reviewed. Studies or reports that described fewer than 10 patients were excluded from analysis if multiple series with greater than 10 patients addressing the same issue were available.

## **NUMBER OF SOURCE DOCUMENTS**

Not stated

# METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

#### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

See "Rating Scheme for the Strength of the Recommendations"

#### METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

#### **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

## METHODS USED TO FORMULATE THE RECOMMENDATIONS

**Expert Consensus** 

# DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Guidelines for the appropriate practice of endoscopy are based on critical review of the available data and expert consensus.

#### RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Grade of Recommendation	Clarity of Benefit	Methodologic Strength Supporting Evidence	Implications
-------------------------	--------------------------	--	--------------

Grade of Recommendation	Clarity of Benefit	Methodologic Strength Supporting Evidence	Implications
1A	Clear	Randomized trials without important limitations	Strong recommendation; can be applied to most clinical settings
18	Clear	Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws)	Strong recommendation; likely to apply to most practice settings
1C+	Clear	Overwhelming evidence from observational studies	Strong recommendation; can apply to most practice settings in most situations
1C	Clear	Observational studies	Intermediate- strength recommendation; may change when stronger evidence is available
2A	Unclear	Randomized trials without important limitations	Intermediate- strength recommendation; best action may differ, depending on circumstances or patients' or societal values
2B	Unclear	Randomized trials with important limitations (inconsistent results, nonfatal	Weak recommendation; alternative approaches may be better under some circumstances

Grade of Recommendation	Clarity of Benefit	Methodologic Strength Supporting Evidence	Implications
		methodologic flaws)	
2C	Unclear	Observational studies	Very weak recommendation; alternative approaches likely to be better under some circumstances
3	Unclear	Expert opinion only	Weak recommendation; likely to change as data become available

Adapted from Guyatt G, Sinclair J, Cook D, et al. Moving from evidence to action: grading recommendations—a qualitative approach. In: Guyatt G, Rennie D, editors. *Users' guides to the medical literature*. Chicago: AMA Press; 2002. p. 599-608.

#### **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

#### **METHOD OF GUIDELINE VALIDATION**

External Peer Review Internal Peer Review

# **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

This document was reviewed and approved by the Governing Board of the American Society for Gastrointestinal Endoscopy. This document was reviewed and endorsed by the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) Guidelines Committee and Board of Governors.

#### **RECOMMENDATIONS**

#### **MAJOR RECOMMENDATIONS**

Definitions for the grades of recommendation (1A to 3) are provided at the end of the "Major Recommendations."

- 1. Routine testing to include coagulation studies, chest x-ray films, electrocardiogram (ECG), blood cross-matching, hemoglobin level, urinalysis, and chemistry tests are not recommended before endoscopy. (1C)
- 2. All women of child-bearing age should be queried about the possibility of being pregnant. Pregnancy testing may be considered in women of child-bearing age unless there is a history of total hysterectomy, bilateral tubal ligation, or absent menses for 1 year (menopause). (3)
- 3. Consider testing based on the perceived level of risk as determined by the medical history and physical examination as follows:
  - a. Coagulation studies: Active bleeding, known or clinically suspected bleeding disorder, medication risk (e.g., anticoagulant use, prolonged antibiotics), prolonged biliary obstruction, history of abnormal bleeding (e.g., easy bruisability, epistaxis, bleeding after dental procedures), history of liver disease, malabsorption (e.g., sprue), malnutrition, or other conditions associated with acquired coagulopathies (e.g., leukemia) (3)
  - b. Chest x-ray film: Advanced age, significant smoking history, recent upper respiratory tract infection, and severe or decompensated cardiopulmonary disease (3)
  - c. ECG: Advanced age and comorbid illness (e.g., heart disease, arrhythmia, diabetes, hypertension, and electrolyte disturbances), particularly for symptomatic patients undergoing more invasive and prolonged procedures (3)
  - d. Blood cross-matching: Blood transfusion considered likely (3)
  - e. Hemoglobin/hematocrit: Existing anemia, risk factors for bleeding, high risk for adverse events with significant bleeding, advanced liver disease or hematologic disorder, endoscopic procedures associated with a high risk of bleeding complications (3)
  - f. Urinalysis: There are no clear indications for obtaining a urinalysis before endoscopy. **(1C)**
  - g. Chemistry testing: Significant endocrine, renal, or hepatic dysfunction and when taking medications that may further impair function (3)

#### **Definitions:**

Grade of Recommendation	Clarity of Benefit	Methodologic Strength Supporting Evidence	Implications
1A	Clear	Randomized trials without important limitations	Strong recommendation; can be applied to most clinical settings
18	Clear	Randomized trials with important limitations (inconsistent	Strong recommendation; likely to apply to most practice settings

Grade of Recommendation	Clarity of Benefit	Methodologic Strength Supporting Evidence	Implications
		results, nonfatal methodologic flaws)	
1C+	Clear	Overwhelming evidence from observational studies	Strong recommendation; can apply to most practice settings in most situations
1C	Clear	Observational studies	Intermediate- strength recommendation; may change when stronger evidence is available
2A	Unclear	Randomized trials without important limitations	Intermediate- strength recommendation; best action may differ, depending on circumstances or patients' or societal values
2B	Unclear	Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws)	Weak recommendation; alternative approaches may be better under some circumstances
2C	Unclear	Observational studies	Very weak recommendation; alternative approaches likely to be better under some circumstances

Grade of Recommendation	Clarity of Benefit	Methodologic Strength Supporting Evidence	Implications
3	Unclear	Expert opinion only	Weak recommendation; likely to change as data become available

Adapted from Guyatt G, Sinclair J, Cook D, et al. Moving from evidence to action: grading recommendations—a qualitative approach. In: Guyatt G, Rennie D, editors. *Users' guides to the medical literature*. Chicago: AMA Press; 2002. p. 599-608.

#### **CLINICAL ALGORITHM(S)**

None provided

#### **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

#### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

# BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

#### **POTENTIAL BENEFITS**

Appropriate routine laboratory testing before endoscopic procedures

#### **POTENTIAL HARMS**

Not stated

#### **CONTRAINDICATIONS**

#### **CONTRAINDICATIONS**

Although pregnancy is not a contraindication to endoscopic procedures and the use of moderate sedation, there are situations when it is important to be aware of pregnancy status because it may affect certain procedural aspects such as use of fluoroscopy and choice of sedation agents.

# **QUALIFYING STATEMENTS**

## **QUALIFYING STATEMENTS**

- Further controlled clinical studies may be needed to clarify aspects of this statement, and revision may be necessary as new data appear. Clinical consideration may justify a course of action at variance with these recommendations.
- This guideline is designed to assist in the selection of patients for whom testing is performed, but it is not intended to determine how a health care professional applies these results to individual patients.

#### IMPLEMENTATION OF THE GUIDELINE

#### **DESCRIPTION OF IMPLEMENTATION STRATEGY**

An implementation strategy was not provided.

# INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

#### **IOM CARE NEED**

Getting Better Staying Healthy

#### **IOM DOMAIN**

Effectiveness

# **IDENTIFYING INFORMATION AND AVAILABILITY**

#### **BIBLIOGRAPHIC SOURCE(S)**

ASGE Standards of Practice Committee, Levy MJ, Anderson MA, Baron TH, Banerjee S, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Jagannath S, Lichtenstein D, Shen B, Fanelli RD, Stewart L, Khan K. Position statement on routine laboratory testing before endoscopic procedures. Gastrointest Endosc 2008 Nov;68(5):827-32. [61 references] PubMed

# **ADAPTATION**

Not applicable: The guideline was not adapted from another source.

#### **DATE RELEASED**

2008 Nov

# **GUIDELINE DEVELOPER(S)**

American Society for Gastrointestinal Endoscopy - Medical Specialty Society

# **SOURCE(S) OF FUNDING**

American Society for Gastrointestinal Endoscopy

#### **GUIDELINE COMMITTEE**

Standards of Practice Committee

#### **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

Committee Members: Michael J. Levy, MD; Michelle A. Anderson, MD; Todd H. Baron, MD, Chair; Subhas Banerjee, MD; Jason A. Dominitz, MD, MHS; S. Ian Gan, MD; M. Edwyn Harrison, MD; Steven O. Ikenberry, MD; Sanjay Jagannath, MD; David Lichtenstein, MD; Bo Shen, MD; Robert D. Fanelli, MD, SAGES Representative; Leslie Stewart, RN, SGNA Representative; Khalid Khan, MD, NAPSGHAN Representative

## FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

# **ENDORSER(S)**

Society of American Gastrointestinal and Endoscopic Surgeons - Medical Specialty Society

#### **GUIDELINE STATUS**

This is the current release of the guideline.

#### **GUIDELINE AVAILABILITY**

Electronic copies: Available from the <u>American Society for Gastrointestinal</u> Endoscopy Web site.

Print copies: Available from the American Society for Gastrointestinal Endoscopy, 1520 Kensington Road, Suite 202, Oak Brook, IL 60523

#### **AVAILABILITY OF COMPANION DOCUMENTS**

None available

#### **PATIENT RESOURCES**

None available

#### **NGC STATUS**

This NGC summary was completed by ECRI Institute on June 12, 2009.

# **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

#### **DISCLAIMER**

#### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href="http://www.guideline.gov/about/inclusion.aspx">http://www.guideline.gov/about/inclusion.aspx</a>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

#### Copyright/Permission Requests

Date Modified: 7/27/2009

